Some adults with chronic hepatitis B may now have a path to something today's treatments rarely deliver—stopping all ...
Today we shine a light on a study that suggests just how ​misguided and potentially dangerous new US hepatitis B vaccination ...
The findings run counter to updated guidance issued in January 2025 by the U.S. Centers for Disease Control and Prevention ...
Top Democrats on the House Energy and Commerce Committee demanded answers Thursday from the Centers for Disease Control and ...
The approval of Hibsago has created a new market for a handful of biopharmas, including Gilead, Arrowhead, and Vir, to fill ...
Arbutus Biopharma (ABUS) said Thursday the US Food and Drug Administration lifted a clinical hold on its AB-101 treatment for hepatitis B, letting the company run further trials o ...
Welltica+ on MSN
Hepatitis A and B: One causes more than 1 million deaths a year
Two viruses can attack the same organ, yet the way they spread and the damage they cause are remarkably different. While ...
For the first time, many people living with chronic hepatitis B may have a functional cure at hand. The US Food and Drug ...
Changes to federal hepatitis B vaccination recommendations could lead to more childhood infections, according to a new study published Monday.
The US FDA recently approved Hibsago (bepirovirsen), a new drug for chronic hepatitis B that could help control viral ...
A new study projects that delaying or omitting the hepatitis B shot at birth could increase chronic infections among children by 83%. Under the direction of Health Secretary RFK Jr., the CDC ended its ...
GSK has secured US FDA approval for Hibsago in chronic hepatitis B, a first-in-class treatment designed to help patients achieve a functional cure.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results